ID: h-fdda39f6
Hypothesis
CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation
CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation.
🧬 CX3CL1/CX3CR1 axis; target: CX3CR1 receptor activation🩺 immunomics🎯 Composite 46%💱 $0.49▲8.5%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
🧪 Overview
CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["CX3CL1 Fractalkine<br/>Neuron-derived ligand"]
B["CX3CR1 Receptor<br/>Microglial surface"]
C["PI3K/Akt Signaling<br/>Survival pathway activation"]
D["Microglial Surveillance<br/>Homeostatic state maintenance"]
E["Synaptic Protection<br/>Reduced excitotoxicity"]
F["Amyloid Plaque<br/>Microglial Clearing"]
G["CX3CL1 Mimetic Peptide<br/>Therapeutic intervention"]
H["Tau Pathology Reduction<br/>AD progression slowing"]
A --> B
B --> C
C --> D
D --> E
D --> F
E --> H
F --> H
G -->|"activates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Contradicts
CX3CR1 deficiency reduces Aβ deposition in APP/PS1 mice (opposite effect on tau) - fundamental therapeutic dilemma
Contradicts
sCX3CL1 can function as a chemokine attracting CX3CR1+ cells toward pathology - potentially beneficial
Contradicts
Human CX3CR1 is expressed at much higher levels on mouse microglia than human microglia; responses may differ qualitatively
Contradicts
sCX3CL1 elevation may represent compensatory upregulation attempting to restore neuron-microglia communication
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CX3CL1
No curated PDB or AlphaFold mapping for CX3CL1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CX3CL1/CX3CR1 axis; target: CX3CR1 receptor activation from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CX3CL1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.4%
Volatility
Low
0.0118
Events (7d)
2
Price History
▲8.5%💾 Resource Usage
LLM Tokens
36,998
$0.1110
Total Cost
$0.1110
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6 mice with established high-fat diet-induced atherosclerosis (12 weeks of HFD) receive daily intraperitoneal CX3CL1 mimetic peptide (10 mg/kg) for 8 weeks, THEN aortic root plaque area will | Reduction in atherosclerotic plaque burden and systemic inflammatory markers | — no observation — | pending | 0.65 |
| IF primary human macrophages are pre-treated with CX3CL1 mimetic peptide (1 μM) for 30 minutes before stimulation with oxLDL (50 μg/mL), THEN CX3CR1 surface internalization will increase by ≥40% and d | Disruption of CX3CR1-mediated pro-inflammatory signaling in human macrophages | — no observation — | pending | 0.70 |
🔮 Falsifiable Predictions (2)
pendingconf 70%
IF primary human macrophages are pre-treated with CX3CL1 mimetic peptide (1 μM) for 30 minutes before stimulation with oxLDL (50 μg/mL), THEN CX3CR1 surface internalization will increase by ≥40% and downstream p65 NF-κB phosphorylation will decrease by ≥35% compared to oxLDL-only stimulation within
Predicted outcome: Disruption of CX3CR1-mediated pro-inflammatory signaling in human macrophages
Falsification: CX3CR1 internalization <20%, no significant reduction in p-p65 levels, or paradoxical increase in inflammatory cytokine secretion
pendingconf 65%
IF C57BL/6 mice with established high-fat diet-induced atherosclerosis (12 weeks of HFD) receive daily intraperitoneal CX3CL1 mimetic peptide (10 mg/kg) for 8 weeks, THEN aortic root plaque area will decrease by ≥25% and serum IL-6/MCP-1 levels will decline by ≥30% compared to vehicle-treated contro
Predicted outcome: Reduction in atherosclerotic plaque burden and systemic inflammatory markers
Falsification: No significant difference in plaque area (p > 0.05) or <15% reduction in inflammatory markers between treatment and control groups
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.